Guo Ailan, Marinaro William, Hu Peidi, Sinko Patrick J
Department of Pharmaceutics, School of Pharmacy, Rutgers University, Piscataway, New Jersey 08854, USA.
Drug Metab Dispos. 2002 Apr;30(4):457-63. doi: 10.1124/dmd.30.4.457.
Multidrug resistance conferred to cancer cells is often mediated by the expression of efflux transporter "pumps". It is also believed that many of the same transporters are involved in drug efflux from numerous normal endothelial and epithelial cell types in the intestine, brain, kidney, and liver. Etoposide transport kinetics were characterized in Caco-2 cells and in well established Madin-Darby canine kidney (MDCKII) cell lines that were stably-transfected with a human cDNA encoding P-glycoprotein (Pgp), human multidrug resistance protein (MRP1), or the canalicular multispecific organic anion (cMOAT) transporters to determine the roles of these transporters in etoposide efflux. Etoposide transport kinetics were concentration-dependent in the MDCKII-MDR1 and MDCKII-cMOAT cells. The apparent secretory Michaelis constant (Km) and carrier-mediated permeability (Pc) values for Pgp and cMOAT were 254.96 +/- 94.39 microM and 5.96 +/- 0.41 x 10(-6) cm/s and 616.54 +/- 163.15 microM and 1.87 +/- 0.10 x 10(-5) cm/s, respectively. The secretory permeability of etoposide decreased significantly in the basal to apical (B to A) (i.e., efflux) direction, whereas the permeability increased 2.3-fold in the apical to basal (A to B) direction in MDCKII-MDR1 cells in the presence of elacridar (GF120918). Moderate inhibition of etoposide efflux by leukotriene C4 (LTC4) was observed in MDCKII-cMOAT cells. Furthermore, etoposide inhibited LTC4 efflux, confirming the involvement of cMOAT. The flux of etoposide in MDCKII-MRP1 cells was similar to that in MDCKII/wt control cells. The current results demonstrate that the secretory transport mechanism of etoposide involves multiple transporters, including Pgp and cMOAT but not MRP1. These results demonstrate that Pgp and cMOAT are involved in the intestinal secretory transport of etoposide. Since the intestinal secretion of etoposide was previously reported in the literature, it also suggests that they may be involved in the in vivo intestinal secretion of etoposide; however, mechanistic in vivo studies are required to confirm this.
赋予癌细胞的多药耐药性通常由外排转运蛋白“泵”的表达介导。人们还认为,许多相同的转运蛋白参与了药物从肠道、大脑、肾脏和肝脏中多种正常内皮细胞和上皮细胞类型的外排。在稳定转染了编码P-糖蛋白(Pgp)、人多药耐药蛋白(MRP1)或小管多特异性有机阴离子(cMOAT)转运蛋白的人cDNA的Caco-2细胞和成熟的Madin-Darby犬肾(MDCKII)细胞系中,对依托泊苷的转运动力学进行了表征,以确定这些转运蛋白在依托泊苷外排中的作用。在MDCKII-MDR1和MDCKII-cMOAT细胞中,依托泊苷的转运动力学呈浓度依赖性。Pgp和cMOAT的表观分泌米氏常数(Km)和载体介导的渗透率(Pc)值分别为254.96±94.39微摩尔和5.96±0.41×10^(-6)厘米/秒以及616.54±163.15微摩尔和1.87±0.10×10^(-5)厘米/秒。在存在艾拉司群(GF120918)的情况下,MDCKII-MDR1细胞中依托泊苷的分泌渗透率在基底到顶端(B到A)(即外排)方向上显著降低,而在顶端到基底(A到B)方向上渗透率增加了2.3倍。在MDCKII-cMOAT细胞中观察到白三烯C4(LTC4)对依托泊苷外排有中度抑制作用。此外,依托泊苷抑制LTC4外排,证实了cMOAT的参与。MDCKII-MRP1细胞中依托泊苷的通量与MDCKII/野生型对照细胞中的通量相似。目前的结果表明,依托泊苷的分泌转运机制涉及多种转运蛋白,包括Pgp和cMOAT,但不包括MRP1。这些结果表明,Pgp和cMOAT参与了依托泊苷的肠道分泌转运。由于先前文献中报道了依托泊苷的肠道分泌,这也表明它们可能参与了依托泊苷的体内肠道分泌;然而,需要进行体内机制研究来证实这一点。